Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

myRocky vs Remi Meds

myRocky
Graded #487

Higher grade

vs+3
Remi Meds
Graded #493

Lower grade

The verdict

myRocky takes it — 51.4/100 to 48.4/100.

myRocky grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. myRocky is a Canadian-incorporated multi-product telehealth platform (Rocky Health Inc., Ontario) that markets brand-name GLP-1s — Ozempic, Mounjaro, and Wegovy — to US patients, with no compounded products.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
34
34
Dose & formulationRemi Meds +1
53
54
Clinical oversightmyRocky +10
64
54
Labs & monitoringmyRocky +2
52
50
FulfillmentmyRocky +17
70
53
Contract termsRemi Meds +14
41
55
myRocky · left barRemi Meds · right bar

The numbers

MetricmyRockyRemi Meds
WeighScore51.4/10048.4/100
GradeCC
Scorecard rank#487#493
SemaglutideNot disclosed$249/mo (0.25 mg dose, compounded)
TirzepatideNot disclosed$349/mo (2.25 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Remi Meds

Graded #493 · C

Strengths

  • Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
  • LegitScript verification badge on the homepage
  • Publishes 503A FDCA compliance language on the tirzepatide page
  • Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
  • Operating corporate entity disclosed (T-C Health Co)

Where it loses points

  • No named medical director, founder, or physician on any public page
  • States served not listed — 'nationwide' claim with no per-state detail
  • Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
  • Year founded and corporate history are opaque
  • Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard